Profile data is unavailable for this security.
About the company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
- Revenue in SEK (TTM)25.44bn
- Net income in SEK3.51bn
- Incorporated1939
- Employees1.81k
- LocationSwedish Orphan Biovitrum AB (publ)Tomtebodavagen 23ASOLNA 171 65SwedenSWE
- Phone+46 86972000
- Websitehttps://www.sobi.com/